Cargando…
Rituximab: A viable treatment option for epoetin-induced pure red cell aplasia
Pure red cell aplasia (PRCA) due to neutralizing antibodies can rarely develop following treatment with epoetin. The treatment of this condition is generally unsatisfactory and immunosuppression is often recommended, which improves chances of hematological recovery. We describe a case of PRCA due to...
Autores principales: | Mahajan, S. A., Nandagopal, N., Soni, M., Annigeri, R. A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications & Media Pvt Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4663775/ https://www.ncbi.nlm.nih.gov/pubmed/26664213 http://dx.doi.org/10.4103/0971-4065.156897 |
Ejemplares similares
-
Pure red cell aplasia induced by epoetin zeta
por: Panichi, Vincenzo, et al.
Publicado: (2016) -
Rituximab therapy for pure red cell aplasia due to anti-epoetin antibodies in a woman treated with epoetin-alfa: a case report
por: Behler, Caroline M, et al.
Publicado: (2009) -
Pure red cell aplasia after treatment of renal anaemia with epoetin theta
por: Herrington, W., et al.
Publicado: (2013) -
Resolution of epoetin‐induced pure red cell aplasia, successful re‐challenge with roxadustat
por: Wu, Yunzhou, et al.
Publicado: (2020) -
Antibody-mediated pure red cell aplasia (PRCA) on switching from darbepoetin alfa to epoetin beta: what are the implications?
por: Assunção, José, et al.
Publicado: (2008)